Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23023089 | 0.91 | SIGMAR1 (0.54) | SIGMAR1MEN1KMT2ATDP1 | |
| SCHEMBL23023116 | 0.90 | SIGMAR1 (0.55) | SIGMAR1MEN1KMT2ATDP1 | |
| SCHEMBL4482137 | 0.82 | KDM1A (0.48) | SIGMAR1MEN1KMT2A | |
| SCHEMBL22495345 | 0.81 | SIGMAR1 (0.63) | SIGMAR1MEN1KMT2ATDP1 | |
| SCHEMBL23022866 | 0.78 | SIGMAR1 (0.69) | SIGMAR1MEN1KMT2ATDP1 | |
| SCHEMBL10425868 | 0.78 | SIGMAR1 (0.73) | SIGMAR1MEN1KMT2ATDP1 | |
| SCHEMBL23553927 | 0.77 | MEN1 (0.52) | HTR5ASIGMAR1MEN1KMT2ATDP1 | |
| SCHEMBL23023177 | 0.77 | SIGMAR1 (0.77) | SIGMAR1MEN1KMT2ATDP1 | |
| SCHEMBL21254320 | 0.77 | CXCR4 (0.59) | — | |
| SCHEMBL23023029 | 0.77 | SIGMAR1 (0.77) | SIGMAR1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | HTR5A 3362/4885SIGMAR1 2321/4885MEN1 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.